All News

12 September 2011

Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy ResponseAntibodies

12 September 2011

FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI Supplemental Biologics License ApplicationAntibodies

9 September 2011

Sucampo and Numab Sign Drug Discovery CollaborationAntibodies

9 September 2011

F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted BiologicsAntibodies

8 September 2011

Elusys Therapeutics, Inc. Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax InfectionAntibodies

8 September 2011

Protalix BioTherapeutics’ Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of HematologyAntibodies

7 September 2011

Astellas Pharma signs a license agreement with Evec for a fully-human antibodyAntibodies

1 September 2011

AnaptysBio Successfully Generates Therapeutic Antibodies in Partnership with a Leading Global PharmaAntibodies

1 September 2011

MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple MyelomaAntibodies

31 August 2011

Richter and STADA cooperate for development of two biosimilar products, two monoclonal antibodies: Rituximab and TrastuzumabAntibodies

29 August 2011

Zymeworks Inc. Announces Collaboration with Merck to Develop Bi-specific Antibody TherapeuticsAntibodies

29 August 2011

Adimab Announces New Discovery Programs with Biogen Idec and Novo NordiskAntibodies

25 August 2011

Peregrine Reports Promising 20.7 Month Median Overall Survival From Phase II Advanced Breast Cancer TrialAntibodies

25 August 2011

Life Extension Announces Recruitment for Alzheimer’s Clinical Trial in South FloridaAntibodies

23 August 2011

Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Hodgkin LymphomaAntibodies

23 August 2011

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck CancerAntibodies

22 August 2011

Amgen Announces PDUFA Date for XGEVA Supplemental Biologics License ApplicationAntibodies

22 August 2011

Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy PlatformAntibodies

22 August 2011

PAT-SM6 Antibody Detected in Patient Tumours; Shows Intra-Tumoural ActivityAntibodies

19 August 2011

Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS (Brentuximab Vedotin) for Two IndicationsAntibodies

17 August 2011

Regeneron Announces Review of Biologics License Application for EYLEA (aflibercept injection) Extended by Three Months by FDAAntibodies

17 August 2011

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent LymphomaAntibodies

17 August 2011

Patrys Anti-Cancer Product Shows Promise in Multiple MyelomaAntibodies

16 August 2011

4-Antibody AG Forms Collaboration with Human Genome SciencesAntibodies

10 August 2011

Boehringer Ingelheim licenses ProBioGen’s novel GlymaxX technologyAntibodies

9 August 2011

Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple SclerosisAntibodies

8 August 2011

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Chemotherapy in Second Line Aggressive LymphomaAntibodies

5 August 2011

Roche’s investigational treatment for asthma met its primary endpoint in a phase II studyAntibodies

5 August 2011

Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritisAntibodies

1 August 2011

Femta Pharmaceuticals Announces IND Filing of FM101, a Novel Monoclonal Antibody Targeting IL-6 with Potent Anti-Inflammatory ActivityAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

B7-H4 Targeted Antibody Therapy Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Report Package: Bispecific Antibodies

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount